Effective treatment of advanced Hodgkin lymphoma with a modified BEACOPP regimen for a patient with demyelinating hereditary motor and sensory neuropathy type 1 (HMSN1)

Treatment for Hodgkin lymphoma (HL) in adults comprises substantial risk of chemotherapy‐induced peripheral neurotoxicity. Here, we describe the case of patient with Charcot–Marie–Tooth disease or HSMN1 and advanced Hodgkin lymphoma undergoing treatment with modified BEACOPP achieving complete remis...

Descripción completa

Detalles Bibliográficos
Autores principales: Hess, Patrick P., Ventura Ferreira, Monica S., Rolles, Benjamin, Kirschner, Martin, Holtbernd, Florian, Tometten, Mareike, Brümmendorf, Tim H., Beier, Fabian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069391/
https://www.ncbi.nlm.nih.gov/pubmed/35540715
http://dx.doi.org/10.1002/ccr3.5766
Descripción
Sumario:Treatment for Hodgkin lymphoma (HL) in adults comprises substantial risk of chemotherapy‐induced peripheral neurotoxicity. Here, we describe the case of patient with Charcot–Marie–Tooth disease or HSMN1 and advanced Hodgkin lymphoma undergoing treatment with modified BEACOPP achieving complete remission without major aggravation of neurological symptoms.

Ejemplares similares